Autoimmune hemolytic anemia

From Citizendium
Revision as of 15:09, 22 December 2014 by imported>Robert Badgett
Jump to navigation Jump to search

In hematology, Autoimmune hemolytic anemia (AIHA) is an "acquired hemolytic anemia due to the presence of autoantibodies which agglutinate or lyse the patient's own red blood cells."[1]

Classification

Diagnosis

Treatment

As of 2010, no randomized controlled trials were available.[6] Subsequent studies are below.

Rituximab, a monoclonal antibody, was found to be safe by a systematic review of 21 studies, although only one was a randomized controlled trials.[7]

References